SMLE obstetrics & gynecology questions

Naegele's rule estimates the expected date of delivery by adding 7 days to the first day of the last menstrual period, then subtracting 3 months (or adding 9 months), assuming a 28-day cycle with ovulation on day 14. Starting from 10 April: add 7 days = 17 April, then subtract 3 months = 17 January. This rule assumes regular cycles; it is adjusted for women with longer or shorter cycles or confirmed by early ultrasound dating.

• A. This result would correspond to a different last menstrual period date.
• B. This subtracts 7 days instead of adding them.
• D. This is two days off from the correct calculation.

When the discrepancy between LMP-based and first-trimester ultrasound (crown-rump length) dating exceeds 5-7 days (up to 14 weeks), the pregnancy should be redated using the ultrasound, which is more accurate because ovulation timing is unreliable, especially with irregular cycles. Crown-rump length measurement in the first trimester has the smallest margin of error of any dating method, generally within 3-5 days. This redating affects timing of screening tests, induction decisions, and assessment of fetal growth later in pregnancy.

• A. Averaging two dating methods is not a recognized practice and introduces inaccuracy.
• C. Redating should occur now based on the discrepancy; delaying is unnecessary and reduces the accuracy benefit of early ultrasound dating.
• D. LMP dating is unreliable with irregular cycles and is superseded by first-trimester ultrasound when discrepant.

Combined first-trimester screening performed between 11 and 13 weeks 6 days consists of nuchal translucency measurement by ultrasound combined with maternal serum pregnancy-associated plasma protein-A (PAPP-A) and free beta-hCG. Low PAPP-A and increased nuchal translucency, with either increased or decreased hCG depending on the trisomy, raise the risk estimate for trisomy 21, 18, or 13. This combined test has a detection rate for Down syndrome of roughly 85-90% with a 5% false-positive rate. The triple and quadruple tests are second-trimester serum screens performed between 15 and 20 weeks and do not include nuchal translucency.

• A. The quadruple test is a second-trimester screen and does not include nuchal translucency.
• B. The triple test is a second-trimester biochemical screen performed without an ultrasound nuchal translucency component.
• C. Alpha-fetoprotein is a second-trimester marker and is not part of first-trimester combined screening.

For women at average risk of neural tube defects, the recommended folic acid dose is 0.4 mg (400 micrograms) daily, ideally started at least one month before conception and continued through the first 12 weeks of pregnancy, since the neural tube closes by around day 28 after conception. High-dose folic acid (4-5 mg daily) is reserved for women at increased risk, such as those with a prior pregnancy affected by a neural tube defect, diabetes, or taking antiepileptic drugs. Starting supplementation only after a positive pregnancy test is too late, as neural tube closure occurs very early, often before pregnancy is recognized.

• A. Folic acid must be started before and in early pregnancy, as the neural tube has already closed by the second trimester.
• B. This high dose is reserved for women at increased risk of neural tube defects, not average-risk women.
• D. Starting only after a positive pregnancy test misses the critical period of neural tube closure in early gestation.

Routine antenatal anti-D prophylaxis is recommended for all Rh-negative women with a negative antibody screen at around 28 weeks of gestation, regardless of the partner's or fetus's Rh status, because this is the period of highest risk for silent fetomaternal hemorrhage causing sensitization. A further dose is given after delivery if the baby is confirmed Rh-positive. Determining fetal Rh status via invasive testing is not required before giving routine prophylaxis and is reserved for specific indications. Waiting until birth would miss the protective window during the third trimester when sensitization risk is highest.

• A. Waiting until birth misses the antenatal prophylaxis window, which protects against sensitization occurring in the third trimester.
• C. Anti-D should be given routinely at 28 weeks regardless of bleeding, not only if a sensitizing event occurs.
• D. Invasive testing to determine fetal Rh status is unnecessary and carries procedural risk; routine prophylaxis is given irrespective of fetal Rh status.

New-onset hypertension (systolic ≥140 mmHg or diastolic ≥90 mmHg) after 20 weeks gestation, without proteinuria (protein-to-creatinine ratio <0.3 mg/mg) or evidence of maternal end-organ dysfunction (normal platelets, creatinine, liver enzymes, no severe-range blood pressure, no cerebral or visual symptoms), is classified as gestational hypertension. This condition requires close monitoring because up to 25% of cases progress to preeclampsia. The diagnosis is purely blood pressure-based once preeclampsia criteria are excluded.

• A. Severe features such as blood pressure ≥160/110 mmHg, thrombocytopenia, or elevated liver enzymes are absent.
• C. There is no history of hypertension before 20 weeks gestation or at booking to support chronic hypertension.
• D. Preeclampsia requires proteinuria or another marker of end-organ dysfunction, both absent here.

Magnesium sulfate acts as a physiological antagonist at the NMDA receptor, blocking calcium influx into neurons and reducing cerebral vasospasm and excitotoxic neuronal injury. This action, combined with mild cerebral vasodilation, underlies its efficacy in preventing and treating eclamptic seizures. Unlike phenytoin or benzodiazepines, its anticonvulsant effect is not primarily through sodium channel blockade or GABA potentiation. The Magpie trial established magnesium sulfate as superior to other anticonvulsants for this indication.

• A. GABA-A potentiation describes the action of benzodiazepines, not magnesium.
• C. This is the mechanism of drugs such as phenytoin, not magnesium sulfate.
• D. Magnesium sulfate does not act through hepatic enzyme inhibition.

Loss of deep tendon reflexes, respiratory depression, and altered consciousness are signs of magnesium toxicity, which occurs because magnesium competes with calcium at the neuromuscular junction, impairing acetylcholine release. The infusion must be stopped immediately, and intravenous calcium gluconate (1 g over 10 minutes) is given as the specific antidote to displace magnesium and restore neuromuscular transmission. Supportive measures including oxygen and ventilatory support may also be needed. Serum magnesium levels should be checked to confirm toxicity.

• B. Toxicity with absent reflexes and respiratory depression requires stopping the infusion, not merely reducing the rate.
• C. Naloxone reverses opioid toxicity and has no role in magnesium toxicity.
• D. Switching routes does not address the current toxic magnesium level and delays definitive treatment.

Intravenous labetalol is a first-line agent for acute severe hypertension in pregnancy, acting as a combined alpha-1 and beta blocker that lowers blood pressure without significant reflex tachycardia and with a favorable safety profile for the fetus. It is given in incremental intravenous boluses (typically starting at 20 mg) with reassessment every 10-20 minutes. Immediate-release oral nifedipine (not extended-release) is an alternative first-line option when intravenous access is delayed. Hydralazine is also acceptable but is more associated with maternal hypotension and headache.

• A. Sodium nitroprusside risks fetal cyanide toxicity and is reserved for cases refractory to standard agents.
• B. Extended-release nifedipine has a slow onset unsuitable for acute severe hypertension; immediate-release oral nifedipine is preferred in that situation.
• D. Methyldopa has a slow onset of action and is used for chronic, not acute severe, hypertension.

HELLP syndrome is defined by the triad of microangiopathic hemolysis (evidenced by schistocytes and elevated lactate dehydrogenase), elevated liver enzymes (aspartate aminotransferase or alanine aminotransferase), and thrombocytopenia (platelet count below 100,000/µL). It is considered a severe variant of preeclampsia and carries risks of hepatic rupture, disseminated intravascular coagulation, and placental abruption. Diagnosis relies on these three laboratory components rather than renal or coagulation parameters alone. Delivery is the definitive treatment once the mother is stabilized.

• A. Proteinuria and hyperuricemia support a preeclampsia diagnosis but are not part of the HELLP triad.
• C. Elevated creatinine and prolonged prothrombin time are not core diagnostic criteria for HELLP syndrome.
• D. Hypofibrinogenemia and elevated D-dimer suggest disseminated intravascular coagulation, a complication rather than the defining triad of HELLP.

Poorly controlled gestational diabetes causes fetal hyperinsulinemia, which promotes disproportionate growth of insulin-sensitive tissues such as the shoulders and trunk relative to the head, leading to macrosomia and increased shoulder-to-head ratio. This predisposes to shoulder dystocia, classically recognized by the 'turtle sign,' where the fetal head retracts against the perineum after delivery because the anterior shoulder is impacted behind the pubic symphysis. Risk factors include estimated fetal weight above 4000 g, maternal diabetes, and prior shoulder dystocia. Management requires immediate recognition and maneuvers such as McRoberts position and suprapubic pressure, as excessive traction risks brachial plexus injury and fetal hypoxia.

• A. Placental abruption presents with vaginal bleeding and a tender, hypertonic uterus before delivery of the fetal head, not as an intrapartum obstruction after head delivery.
• C. Uterine rupture presents with sudden severe abdominal pain, fetal heart rate abnormalities, and loss of station, not head retraction after delivery of the head.
• D. Cord prolapse presents with a palpable or visible umbilical cord before the fetal head delivers, with sudden fetal bradycardia, not with retraction of an already delivered head.

Propylthiouracil (PTU) is preferred during the first trimester because methimazole and carbimazole are associated with a rare but characteristic embryopathy, including aplasia cutis, choanal atresia, and esophageal atresia, when exposure occurs during organogenesis. PTU carries a small risk of hepatotoxicity, so it is typically switched to methimazole after the first trimester once organogenesis is complete, to reduce the cumulative risk of liver injury. This trimester-specific switching strategy balances teratogenic risk against hepatotoxic risk. Radioactive iodine is absolutely contraindicated throughout pregnancy because it crosses the placenta and ablates the fetal thyroid.

• A. Radioactive iodine is contraindicated at any stage of pregnancy because it crosses the placenta and destroys the fetal thyroid gland.
• C. Carbimazole is a prodrug of methimazole and carries the same first-trimester teratogenic risk.
• D. Methimazole is avoided in the first trimester due to the risk of embryopathy such as aplasia cutis and choanal atresia.

Asymptomatic bacteriuria in pregnancy, defined as a single clean-catch urine culture with at least 10^5 CFU/mL of a single organism without symptoms, should be treated with a short course of antibiotics chosen based on local sensitivity patterns and pregnancy safety. Treatment reduces the risk of progression to acute pyelonephritis, which is associated with preterm labor and low birth weight. Unlike in non-pregnant women, asymptomatic bacteriuria in pregnancy is always treated because of this elevated risk. A repeat culture to confirm infection before treating, or deferring treatment until symptoms occur, delays therapy and increases the risk of ascending infection.

• B. Treatment should not be delayed for a confirmatory culture, as pregnant women with asymptomatic bacteriuria are treated on a single positive culture to prevent pyelonephritis.
• C. Long-term suppressive prophylaxis is reserved for recurrent infections after treatment failure, not as initial management of a first positive culture.
• D. Reassurance without treatment is inappropriate because, unlike in nonpregnant women, asymptomatic bacteriuria in pregnancy is treated regardless of symptoms.

Placenta previa classically presents with painless, bright red vaginal bleeding in the third trimester, with a soft, non-tender uterus and a reassuring fetal heart rate pattern unless significant maternal blood loss has occurred. This is because the bleeding originates from disruption of placental vessels overlying the cervix as the lower uterine segment stretches, without associated myometrial irritability. Placental abruption, in contrast, typically presents with painful bleeding and a tender, hypertonic uterus due to retroplacental blood causing uterine irritability. The absence of pain and uterine tenderness here points away from abruption and toward previa.

• A. Uterine rupture presents with severe abdominal pain, fetal heart rate abnormalities, and often loss of fetal station, usually in a woman with a prior uterine scar.
• C. Placental abruption typically presents with painful vaginal bleeding and a tender, hypertonic uterus, which are absent in this case.
• D. Vasa previa presents with painless bleeding following rupture of membranes and is associated with acute fetal distress or fetal bradycardia, not a reactive fetal heart rate.

Once placenta previa is confirmed or strongly suspected, digital vaginal examination must be avoided because it can disrupt the low-lying placenta, provoke severe hemorrhage, and precipitate an obstetric emergency. The appropriate approach is admission for close observation, maternal and fetal monitoring, and planning for delivery based on gestational age, bleeding severity, and placental location, often by cesarean section. A gentle speculum examination may sometimes be used cautiously to look for other causes of bleeding such as cervical lesions, but digital examination remains contraindicated when previa is confirmed. Artificial rupture of membranes is not performed in previa, as it does not stop placental bleeding and can worsen the situation.

• A. Artificial rupture of membranes does not address bleeding from the previa and can worsen hemorrhage and cord complications.
• B. Digital vaginal examination can dislodge the previa and precipitate massive hemorrhage, so it is contraindicated once previa is confirmed.
• D. Even a speculum examination followed by digital assessment risks triggering bleeding and is not the standard next step once previa is already confirmed by ultrasound.

Transabdominal ultrasound is the best initial investigation for painless third-trimester bleeding because it can rapidly and safely localize the placenta and identify or exclude placenta previa without risk of provoking further hemorrhage. If the placental edge cannot be clearly visualized, transvaginal ultrasound can be performed safely even in suspected previa, as the probe does not need to contact the cervix directly and is more accurate for assessing the relationship between the placental edge and the internal os. Digital examination is unsafe until previa has been excluded. MRI and cervical swabs are not first-line for this presentation and introduce delay without added benefit in the acute setting.

• A. Digital examination should not be performed until placenta previa has been excluded, as it may provoke severe bleeding.
• B. Speculum examination with cervical swabs does not localize the placenta and could miss or delay diagnosis of previa as the cause of bleeding.
• C. MRI is not the first-line investigation for antepartum bleeding; it is reserved for specific indications such as suspected placenta accreta spectrum after ultrasound.

Vasa previa occurs when fetal vessels run through the membranes over or near the internal cervical os, unprotected by placental tissue or the umbilical cord, putting them at risk of laceration when the membranes rupture. Risk factors include velamentous cord insertion, bilobed or succenturiate-lobed placentas, and pregnancies conceived through in vitro fertilization. Diagnosis is made by transvaginal ultrasound with color Doppler, which identifies the aberrant vessels crossing near the cervix. Antenatal diagnosis allows planned cesarean delivery before labor or membrane rupture, which dramatically improves fetal survival compared with intrapartum rupture of vasa previa vessels.

• A. Uterine rupture is a clinical intrapartum emergency with uterine wall disruption, not an antenatal ultrasound finding of membranous fetal vessels.
• C. Placenta previa refers to placental tissue, not unsupported fetal vessels, covering or encroaching on the internal os.
• D. Placental abruption is premature separation of the placenta from the uterine wall, presenting with pain and bleeding, not an ultrasound finding of exposed fetal vessels.

A Couvelaire uterus is a recognized complication of severe placental abruption in which blood extravasates from the retroplacental hemorrhage into the myometrium and beneath the serosa, giving the uterus a diffusely bruised, purple-blue, mottled appearance. This occurs because the force and volume of retroplacental bleeding dissect through the uterine wall rather than remaining confined behind the placenta. Although it looks alarming at laparotomy, a Couvelaire uterus usually still contracts adequately and is not itself an indication for hysterectomy unless accompanied by uncontrollable hemorrhage or coagulopathy such as disseminated intravascular coagulation. Severe abruption with a Couvelaire uterus is also a known trigger for consumptive coagulopathy, so coagulation studies should be checked.

• A. Uterine rupture presents as a visible defect or tear in the uterine wall, not diffuse bruising of an intact uterine surface.
• B. Amniotic fluid embolism presents with sudden maternal cardiovascular collapse and respiratory failure, not a specific bruised appearance of the uterus.
• D. Uterine atony refers to failure of the uterus to contract after delivery, not a diffuse bruised discoloration of the uterine wall from extravasated blood.

Recurrent late decelerations with a normal baseline and moderate variability represent a non-reassuring (suspicious/category II) trace reflecting uteroplacental insufficiency rather than an immediately life-threatening pattern. The first-line response is conservative measures: maternal repositioning (left lateral), intravenous fluid bolus, stopping oxytocin if running, and correcting maternal hypotension, followed by reassessment of the trace. Immediate delivery is reserved for category III (pathological) traces with absent variability, bradycardia, or a sinusoidal pattern. Fetal scalp stimulation is used to assess fetal wellbeing when variability is reduced, not as the primary response to late decelerations.

• A. Scalp stimulation assesses reduced variability, not the primary response to recurrent late decelerations with preserved variability.
• C. Immediate cesarean is reserved for category III (pathological) traces; this is category II and warrants conservative measures first.
• D. The trace is non-reassuring, not normal, so routine monitoring without intervention is inappropriate.

Active management of the third stage of labor is the standard of care to prevent postpartum hemorrhage and consists of prophylactic uterotonic administration immediately after delivery of the baby, controlled cord traction, and uterine massage after placental delivery. Intramuscular or intravenous oxytocin (10 units) is the first-line uterotonic because of its rapid onset, effectiveness, and favorable side-effect profile compared with other agents. Misoprostol is a reasonable alternative only when oxytocin is unavailable, such as in low-resource settings without cold-chain storage. Fundal massage is part of ongoing postpartum surveillance but is not the initial pharmacologic prophylactic step.

• A. Misoprostol is a second-line alternative to oxytocin, used when oxytocin is unavailable, not the first-choice agent.
• B. Uterine massage and controlled cord traction follow uterotonic administration; suprapubic pressure alone is not the standard prophylactic measure.
• C. Fundal massage is part of monitoring after placental delivery, not the primary prophylactic step immediately after fetal delivery.

The clinical picture, head retraction against the perineum (the 'turtle sign') and failure of the anterior shoulder to deliver with gentle traction, is diagnostic of shoulder dystocia. The McRoberts maneuver, hyperflexion and abduction of the maternal hips bringing the knees toward the chest, is the recommended first-line maneuver because it straightens the sacrum relative to the spine and rotates the symphysis, often disimpacting the anterior shoulder. It is simple, rapid, and should be attempted before suprapubic pressure or more invasive maneuvers. Excess traction, fundal pressure, and panic should be avoided as they increase the risk of brachial plexus injury.

• A. Suprapubic pressure is used if McRoberts alone fails, not as the very first maneuver, and continued traction risks neonatal injury.
• B. The Zavanelli maneuver is a last-resort measure for cases refractory to all other maneuvers.
• C. Symphysiotomy is an extreme, rarely used measure reserved for maneuvers that have already failed.

Umbilical cord prolapse is an obstetric emergency where the cord descends alongside or below the presenting part, risking compression and fetal hypoxia, as reflected by the sudden severe bradycardia here. Immediate management is to relieve cord compression by manually elevating the presenting part vaginally while the patient is positioned in knee-chest or left-lateral position, and to arrange immediate delivery, almost always by emergency cesarean section unless vaginal delivery is imminent. Attempting to push the cord back into the uterus increases the risk of vasospasm and further compression and is not recommended. Supine positioning with legs elevated alone, without elevating the presenting part, does not relieve compression.

• B. Positioning alone without manually elevating the presenting part does not adequately relieve cord compression.
• C. Manual reduction of the cord into the uterus is not recommended and can worsen vasospasm and compression.
• D. Amnioinfusion has no established role in the emergency management of cord prolapse.

The stepwise management of postpartum hemorrhage due to uterine atony progresses from bimanual massage and first-line oxytocin to additional pharmacologic uterotonics (such as ergometrine, carboprost, or misoprostol) when bleeding persists despite oxytocin and massage. Carboprost (a prostaglandin F2-alpha analogue) is commonly used as a second-line uterotonic, given intramuscularly, when atony continues. Mechanical measures such as balloon tamponade and surgical or radiological interventions (embolization, B-Lynch suture, hysterectomy) are reserved for cases that fail to respond to combined pharmacologic therapy with uterotonics. Hysterectomy is a last resort after conservative and surgical options have failed.

• A. Balloon tamponade is used after pharmacologic measures, including additional uterotonics, have failed to control bleeding.
• C. Uterine artery embolization is a later option for refractory bleeding, typically after pharmacologic and tamponade measures fail, and requires interventional radiology availability.
• D. Hysterectomy is reserved for life-threatening hemorrhage refractory to all other measures, not the first escalation step.

Misoprostol is a prostaglandin E1 analogue that causes uterine contraction without significant vasoconstrictor or hypertensive effect, making it safe in women with chronic hypertension. Ergot alkaloids (ergometrine, methylergometrine) cause generalized vasoconstriction and are contraindicated in hypertension, pre-eclampsia, and cardiac disease because they can precipitate severe hypertension, stroke, or myocardial infarction. Carboprost, a prostaglandin F2-alpha analogue, is relatively contraindicated in asthma due to bronchospasm but is not the best choice here given availability of a safer option for this patient's hypertension. Misoprostol is therefore preferred as a second-line agent in this clinical context.

• A. Caution is needed in asthmatics; it is not the first choice when a hypertension-safe alternative exists.
• B. Same contraindication as ergometrine; ergot derivatives worsen hypertension.
• C. Ergot alkaloids are contraindicated in hypertensive patients due to risk of severe hypertensive crisis.

Puerperal endometritis is a clinical diagnosis based on fever, uterine or lower abdominal tenderness, and purulent or foul-smelling lochia, typically occurring after risk factors such as cesarean delivery, prolonged labor, prolonged rupture of membranes, and multiple vaginal examinations that allow ascending infection from the lower genital tract. Isolated laboratory abnormalities such as mild leukocytosis (expected postpartum) or an elevated CRP without clinical correlation are nonspecific and do not establish the diagnosis. Mild tenderness without fever or abnormal discharge is insufficient, since fever is a required diagnostic criterion. The combination of fever, uterine tenderness, and foul lochia in the setting of known risk factors is the classic diagnostic triad.

• A. Fever is an essential criterion; its absence makes endometritis unlikely.
• C. Mild leukocytosis is a normal postpartum finding and not diagnostic alone.
• D. CRP elevation is nonspecific and can occur postpartum without infection; fever is required.

Postpartum depression is characterized by persistent depressive symptoms lasting beyond two weeks, with functional impairment, typically starting within the first few weeks after delivery and distinguished from the transient, self-limiting postpartum blues. Postpartum blues peaks around day 3-5 and resolves spontaneously within two weeks without impairing the mother's ability to function or care for the baby. Puerperal psychosis presents with hallucinations, delusions, or grossly disorganized behavior and is a psychiatric emergency, which this patient does not have. Brief psychotic disorder also requires psychotic features, which are absent here.

• A. No psychotic features are present, making this diagnosis incorrect.
• C. Puerperal psychosis requires psychotic symptoms such as hallucinations or delusions, which are absent.
• D. Postpartum blues is transient, resolves within two weeks, and does not cause significant functional impairment.

Sheehan syndrome results from ischemic necrosis of the anterior pituitary gland following severe postpartum hemorrhage and hypotension. During pregnancy the anterior pituitary is physiologically enlarged and has increased blood flow demand but relies on a low-pressure portal venous system, making it especially vulnerable to infarction during hypotensive episodes. This leads to varying degrees of hypopituitarism, manifesting as failure of lactation (prolactin deficiency), amenorrhea (gonadotropin deficiency), and fatigue (ACTH and TSH deficiency). Autoimmune hypophysitis (lymphocytic) is a separate entity unrelated to hemorrhage, and ovarian failure or cavernous sinus thrombosis do not explain the global pituitary hormone deficiency seen here.

• A. Autoimmune hypophysitis is a distinct condition not triggered by hemorrhage.
• B. Ovarian failure does not explain failure of lactation, which reflects pituitary prolactin deficiency.
• C. Cavernous sinus thrombosis presents with cranial nerve palsies and orbital signs, not this pattern of hypopituitarism.

In a normally progressing early intrauterine pregnancy, serum beta-hCG typically rises by at least 53-66% over 48 hours. A rise of only about 21% (from 1200 to 1450 IU/L), with no intrauterine sac visible despite a level above the discriminatory zone, is a suboptimal rise suggestive of a pregnancy of abnormal location, including ectopic pregnancy or an early failing pregnancy. This pattern mandates close follow-up with repeat ultrasound and beta-hCG trends rather than reassurance. A normally rising pregnancy would show a much steeper increase, and complete miscarriage would show a rapidly falling, not rising, titer.

• A. Complete miscarriage is associated with a falling, not rising, beta-hCG level.
• B. A normal pregnancy shows a rise of at least 53-66% in 48 hours, which is not met here.
• C. Threatened or impending miscarriage typically presents with bleeding and plateauing or falling levels, not this pattern alone.

Methotrexate is appropriate for ectopic pregnancy when the patient is hemodynamically stable, the mass is small (generally under 3.5-4 cm), there is no fetal cardiac activity, beta-hCG is below approximately 5000 IU/L, and there are no contraindications such as abnormal liver or renal function, blood dyscrasia, or breastfeeding. This patient meets all these criteria, making medical management with methotrexate and serial beta-hCG monitoring the most appropriate first-line option. Surgery is reserved for hemodynamic instability, rupture, contraindications to methotrexate, or failure of medical therapy. Expectant management alone is not appropriate at this beta-hCG level and mass size without evidence of spontaneous resolution.

• B. Laparotomy is unnecessarily invasive when laparoscopy or medical therapy would suffice in a stable patient.
• C. Surgery is reserved for instability, rupture, or contraindications to methotrexate, none present here.
• D. Expectant management is not first-line at this hCG level and size without a clearly declining trend.

Incomplete miscarriage is characterized by an open cervical os with partial passage of products of conception and retained heterogeneous tissue seen on ultrasound, as in this case. Threatened miscarriage presents with bleeding but a closed cervical os and a viable intrauterine pregnancy. Inevitable miscarriage shows an open os with a gestational sac still present but not yet passed, before expulsion has begun. Missed miscarriage refers to fetal demise with a closed cervix and retained, non-expelled products, without bleeding or passage of tissue necessarily occurring. The key distinguishing finding here is partial expulsion with retained tissue on imaging.

• B. Threatened miscarriage requires a closed cervical os, which is not the case here.
• C. Missed miscarriage involves a closed cervix with no expulsion of tissue, unlike this presentation.
• D. Inevitable miscarriage has an open os but products have not yet begun to pass, unlike this partial expulsion.

The diagnosis of antiphospholipid syndrome requires both a clinical criterion (such as recurrent pregnancy loss) and laboratory confirmation with at least one of lupus anticoagulant, anticardiolipin antibodies (IgG or IgM), or anti-beta2-glycoprotein I antibodies, positive on two occasions at least 12 weeks apart, per the revised Sapporo (Sydney) classification criteria. A single antinuclear antibody titer is nonspecific and not part of the diagnostic criteria for antiphospholipid syndrome. A direct Coombs test evaluates for autoimmune hemolytic anemia and is unrelated. An isolated prolonged APTT without confirmatory phospholipid-dependent testing on two separate occasions is insufficient to establish the diagnosis.

• A. ANA is nonspecific and not a diagnostic criterion for antiphospholipid syndrome.
• B. A single APTT measurement without repeat confirmatory antiphospholipid testing does not meet diagnostic criteria.
• D. Coombs test evaluates hemolytic anemia and has no role in antiphospholipid syndrome diagnosis.

A complete mole shows a characteristic 'snowstorm' or 'bunch of grapes' pattern on ultrasound, with diffuse hydropic villi and no fetal parts or amniotic sac, consistent with this case. Markedly elevated hCG (often >100,000 mIU/mL), uterine size greater than dates, early pre-eclampsia, and bilateral theca lutein cysts (from ovarian hyperstimulation by high hCG) are classic features. A partial mole typically has an identifiable fetus/fetal parts with triploidy. The absence of any fetal structures and the very high hCG favor a complete mole over a degenerating normal pregnancy.

• B. Choriocarcinoma usually follows a prior pregnancy and shows invasive disease, not this classic snowstorm pattern at presentation.
• C. Hydropic degeneration of a missed miscarriage does not produce theca lutein cysts or hCG this high.
• D. A partial mole usually shows an identifiable fetus or fetal parts alongside molar change, which are absent here.

Tranexamic acid is an antifibrinolytic that reduces menstrual blood loss by inhibiting plasminogen activation in the endometrium, and it is taken only during menstruation without affecting fertility or ovulation. It is a recommended first-line non-hormonal option for heavy menstrual bleeding in women without structural pathology who wish to avoid hormonal treatment or preserve fertility plans. The levonorgestrel IUS is generally the most effective medical treatment overall but is hormonal and less suitable for a woman wanting a short-term, cycle-only, non-hormonal option before attempting conception soon. Combined pills and cyclic progestins are hormonal and are not her stated preference.

• A. The LNG-IUS is highly effective but is hormonal and intended for longer-term use, not matching her preference.
• C. This is a hormonal method and would not match her preference for a non-hormonal, menses-only treatment.
• D. Cyclic oral progestin is hormonal and less effective than the LNG-IUS or antifibrinolytics for heavy bleeding.

The Rotterdam criteria diagnose PCOS when at least two of three features are present: oligo/anovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasound (12 or more follicles 2-9 mm, or ovarian volume over 10 mL), after excluding other causes. This patient has oligomenorrhea, hirsutism, and polycystic-appearing ovaries, meeting all three criteria. Normal 17-hydroxyprogesterone excludes non-classic congenital adrenal hyperplasia, and normal prolactin and TSH exclude hyperprolactinemia and thyroid dysfunction as alternative causes of irregular cycles.

• A. Premature ovarian insufficiency presents with low ovarian reserve and elevated FSH, not polycystic ovarian morphology.
• B. Normal 17-hydroxyprogesterone excludes congenital adrenal hyperplasia as the cause.
• D. Normal serum prolactin excludes hyperprolactinemia.

In chronic anovulation, as seen in PCOS, the absence of ovulation means no corpus luteum forms and no progesterone is produced to oppose estrogen. The endometrium is continuously stimulated by estrogen, leading to proliferation without the organized shedding that normally follows progesterone withdrawal, resulting in an unstable, overgrown endometrium that sheds irregularly and heavily. This mechanism explains both the irregular timing and heaviness of bleeding and the hyperplastic biopsy findings. Prostaglandin-mediated contraction relates to primary dysmenorrhea, von Willebrand disease is a bleeding disorder, and submucosal fibroids are a structural cause, none of which explain this anovulatory pattern.

• A. A submucosal fibroid is a structural cause of bleeding, not the hormonal mechanism of anovulatory bleeding described here.
• B. Excess prostaglandin-driven contraction explains dysmenorrhea pain, not the anovulatory bleeding pattern in PCOS.
• C. Von Willebrand disease is a coagulation disorder, not the mechanism underlying chronic anovulation in PCOS.

Diagnostic laparoscopy with direct visualization and histological confirmation of endometriotic implants remains the gold standard for definitively diagnosing endometriosis, especially when the classic triad of dysmenorrhea, dyspareunia, and chronic pelvic pain is present with suggestive examination findings such as a fixed retroverted uterus and posterior fornix nodularity. Laparoscopy also allows simultaneous treatment by excision or ablation of visible lesions. CA-125 is neither sensitive nor specific enough for diagnosis. MRI can suggest deep infiltrating disease but does not provide histological confirmation, and empirical hormonal therapy may be used clinically but does not establish a definitive diagnosis.

• A. Empirical medical therapy may relieve symptoms but does not confirm the diagnosis.
• B. CA-125 can be elevated in endometriosis but lacks sufficient sensitivity and specificity to be diagnostic.
• C. MRI is useful for mapping deep infiltrating disease but does not provide the histological confirmation that laparoscopy does.

Adenomyosis typically produces a diffusely and symmetrically enlarged, tender uterus with heterogeneous myometrium, an indistinct or thickened junctional zone, and small myometrial cysts on ultrasound, reflecting ectopic endometrial glands and stroma within the myometrium. Fibroids, in contrast, usually appear as discrete, well-circumscribed hypoechoic masses that distort the uterine contour or cavity, and the uterus is typically firm and often irregularly enlarged rather than diffusely boggy. The absence of a discrete mass here argues against leiomyoma, and an endometrial polyp would appear as a focal intracavitary lesion rather than diffuse myometrial change.

• A. A leiomyoma typically appears as a discrete, well-circumscribed mass, not the diffuse myometrial change described.
• B. An endometrial polyp is a focal intracavitary lesion, not a cause of diffuse myometrial enlargement.
• C. A subserosal fibroid projects from the outer uterine surface as a discrete mass, inconsistent with this diffuse pattern.

Standard infertility workup begins with the simplest, least invasive, and most cost-effective tests, and semen analysis is both non-invasive and identifies a male factor contributing to roughly half of infertility cases. Since the woman has regular cycles suggesting ovulation, and no risk factors point to a specific pathology in either partner, the initial step is semen analysis before proceeding to tests for ovulatory or tubal factors. Hysterosalpingography and laparoscopy assess tubal and pelvic factors but are more invasive and are typically pursued after simpler tests, including semen analysis and confirmation of ovulation, have been completed. AMH assesses ovarian reserve but is not the first step in a standard initial workup.

• A. Diagnostic laparoscopy is invasive and reserved for cases with suspected pelvic pathology, not the initial screening step.
• B. Tubal patency testing is more invasive and is typically performed after semen analysis and ovulation assessment.
• C. AMH assesses ovarian reserve and is used selectively, not as the universal first step in initial infertility evaluation.

Clomiphene citrate is a selective estrogen receptor modulator that binds hypothalamic estrogen receptors and blocks the normal negative feedback of circulating estradiol. The hypothalamus perceives a low-estrogen state, leading to increased GnRH pulse frequency and amplitude, which raises pituitary FSH and LH secretion. This drives recruitment and maturation of an ovarian follicle, and the subsequent LH surge triggers ovulation. It is the long-standing first-line oral agent for ovulation induction in anovulatory infertility, particularly PCOS.

• A. This describes a progestin-type suppressive action, opposite to clomiphene's effect of increasing gonadotropin release.
• B. Clomiphene acts centrally on the hypothalamus, not directly on ovarian granulosa cells.
• D. Clomiphene works indirectly through the hypothalamic-pituitary axis, not by direct ovarian receptor activation.

Dopamine agonists such as cabergoline are first-line therapy for prolactinoma-associated hyperprolactinemia, whether microadenoma or macroadenoma. They act on pituitary lactotroph D2 receptors to suppress prolactin secretion, shrink tumor size, and restore normal gonadotropin pulsatility, thereby resuming ovulation and fertility in most patients. Cabergoline is preferred over bromocriptine due to better tolerability and efficacy. Surgery is reserved for dopamine agonist-resistant or intolerant cases, or those with visual compromise.

• A. Surgery is not first-line for microadenomas and is reserved for medical treatment failure.
• B. Clomiphene does not address the underlying hyperprolactinemia and will not be effective while prolactin remains elevated.
• C. Oral contraceptives do not correct hyperprolactinemia and would not restore ovulation in this fertility-seeking patient.

Ovarian hyperstimulation syndrome is a complication of gonadotropin-based fertility treatment caused by excessive ovarian response to hCG trigger, leading to increased vascular permeability mediated by VEGF. This results in fluid shifting from the intravascular space into third spaces, causing ascites, pleural effusion, hemoconcentration (raised hematocrit), and enlarged multicystic ovaries, as seen in this patient. Severity is classified by the degree of ascites, ovarian size, and laboratory derangement including hematocrit and renal function. Management includes fluid and electrolyte monitoring, thromboprophylaxis, and paracentesis for symptomatic relief in severe cases.

• A. Torsion typically presents with acute unilateral pain, not bilateral ovarian enlargement with ascites and hemoconcentration.
• B. Ectopic pregnancy presents with pain and vaginal bleeding with a positive pregnancy test, not bilateral ovarian enlargement and ascites after stimulation.
• C. Tubo-ovarian abscess presents with fever and pelvic pain in the context of infection, not after ovarian stimulation with this fluid-shift picture.

Bacterial vaginosis results from a shift in vaginal flora from lactobacilli to anaerobic organisms such as Gardnerella vaginalis, producing a thin grey homogeneous discharge with an elevated pH above 4.5 and a positive whiff test. Microscopy classically shows clue cells, which are vaginal epithelial cells with adherent coccobacilli, with minimal inflammatory response, matching this patient's findings. Candidiasis causes thick curdy discharge with pruritus and pseudohyphae on microscopy, and trichomoniasis causes frothy yellow-green discharge with motile flagellated protozoa and many white blood cells. This clinical and microscopic pattern fulfills the Amsel criteria for bacterial vaginosis.

• B. Candidiasis presents with pruritic thick white discharge and pseudohyphae, not clue cells with minimal inflammation.
• C. Trichomoniasis typically shows frothy discharge with motile flagellates and abundant white blood cells on microscopy, not clue cells.
• D. Atrophic vaginitis occurs in estrogen-deficient states and does not produce clue cells or a fishy odor.

This patient meets the minimum clinical criteria for pelvic inflammatory disease: lower abdominal pain with cervical motion or adnexal tenderness in a sexually active woman with no other identified cause, supported by the finding of leukocytes on vaginal secretions. Current CDC and international guidelines recommend empirical coverage for Neisseria gonorrhoeae, Chlamydia trachomatis, and anaerobic/facultative organisms because the causative organism is rarely confirmed at presentation. The standard outpatient regimen is a single intramuscular dose of ceftriaxone combined with 14 days of oral doxycycline, with metronidazole added to cover anaerobes, especially if bacterial vaginosis is also present or if there is a higher risk of tubo-ovarian abscess. Treatment should begin empirically once the diagnosis is suspected, without waiting for microbiologic confirmation, to reduce the risk of tubal scarring and infertility.

• B. This regimen does not reliably cover gonococcal infection and is not the recommended first-line empirical therapy for PID.
• C. Single-dose azithromycin alone is insufficient coverage for gonorrhea and anaerobes in PID.
• D. Fluoroquinolone monotherapy does not adequately cover anaerobes and is limited by rising gonococcal resistance.

Tubo-ovarian abscess develops when ascending infection from untreated or inadequately treated pelvic inflammatory disease spreads to involve the fallopian tube and ovary, forming a complex inflammatory mass. The classic presentation includes fever, leukocytosis, and a tender palpable adnexal mass, with ultrasound showing a complex multiloculated structure containing internal debris consistent with pus and necrotic tissue. Management requires broad-spectrum antibiotics covering anaerobes and gram-negatives, with drainage or surgical intervention if there is no response or if the abscess is large or ruptured. Delay in treating PID is the key risk factor for this complication.

• A. Ectopic pregnancy would show a positive pregnancy test and typically free blood rather than a multiloculated abscess with debris.
• B. Torsion presents with acute sudden-onset pain and a solid-appearing enlarged ovary, not a thick-walled multiloculated abscess with fever and leukocytosis.
• C. Endometrioma typically appears as a homogeneous ground-glass cyst without fever or acute inflammatory signs.

ASC-US is a borderline cytologic finding with a low but real risk of underlying high-grade dysplasia. Current triage algorithms recommend reflex high-risk HPV DNA testing on the same sample: if positive, the patient is referred for colposcopy; if negative, she returns to routine screening intervals. This strategy avoids unnecessary colposcopies in the majority of ASC-US cases, which are HPV-negative and clinically insignificant.

• B. Colposcopy for every ASC-US result over-refers low-risk women and is reserved for HPV-positive results or higher-grade cytology.
• C. Excisional treatment is inappropriate without a tissue diagnosis confirming high-grade disease.
• D. Repeating cytology too soon is an older, less sensitive approach and is not the preferred first step when HPV co-testing is available.

In chronic anovulation, as in polycystic ovary syndrome, the ovary continues to produce estrogen without forming a corpus luteum, so progesterone is never secreted to oppose estrogen's proliferative effect. The endometrium remains in a continuous proliferative state without the regular secretory transformation and shedding that progesterone normally triggers, leading to hyperplasia and, over years, an increased risk of endometrial carcinoma. This is the same mechanism underlying the increased risk seen with obesity, nulliparity, and estrogen-only hormone therapy.

• B. Gonadotropin suppression is not the mechanism; anovulation in PCOS is due to disrupted follicular maturation, not pituitary suppression.
• C. Peripheral aromatization of androgens contributes to estrogen levels but the carcinogenic mechanism is the lack of progesterone opposition, not conversion within the endometrium itself.
• D. Anovulatory cycles by definition lack a luteal phase and therefore lack progesterone surges, which is the problem, not a contributing surge.

CA-125 is a glycoprotein marker that lacks specificity for malignancy and is commonly elevated in benign gynecologic conditions, including endometriosis, fibroids, pelvic inflammatory disease, and even pregnancy or menstruation. In this young patient with ultrasound findings classic for an endometrioma, the moderately elevated CA-125 reflects the underlying endometriosis rather than cancer. CA-125 is more useful for monitoring treatment response and detecting recurrence in a patient already diagnosed with epithelial ovarian cancer than as a standalone diagnostic or screening test.

• A. CA-125 has low sensitivity, especially for early-stage ovarian cancer and non-epithelial tumors, so a normal value cannot reliably exclude malignancy.
• C. Surgical staging is not indicated based on a nonspecific marker alone without strong clinical or imaging suspicion of malignancy.
• D. A single elevated CA-125 does not confirm malignancy, since many benign conditions raise its level.

Migraine with aura is a recognized independent risk factor for ischemic stroke, and estrogen-containing contraceptives further increase this risk through enhanced platelet aggregation and a prothrombotic state. Combining migraine with aura, age over 35 years, and active smoking places this patient in a category where combined hormonal contraception is unacceptable according to the WHO Medical Eligibility Criteria. Progestin-only or non-hormonal methods are preferred alternatives in this setting.

• A. Combined oral contraceptives are not associated with an increased risk of cervical cancer as the primary safety issue here.
• B. Gallbladder disease risk is a recognized but minor association and not the key contraindication driven by her migraine with aura and smoking.
• C. Weight gain is a minor and inconsistently observed side effect, not the defining safety concern in this patient.

The copper IUD releases copper ions that create a sterile inflammatory reaction in the endometrial cavity, generating a toxic environment for sperm motility and ovum viability, which is primarily a pre-fertilization effect. The levonorgestrel-releasing IUD works mainly through local progestin effects that thicken cervical mucus to block sperm penetration and cause endometrial decidualization and atrophy, with only partial and inconsistent suppression of ovulation at standard doses. Neither device relies primarily on systemic suppression of the hypothalamic-pituitary-ovarian axis as its main contraceptive mechanism.

• B. This reverses the mechanisms: cervical mucus thickening is a levonorgestrel effect, and the inflammatory reaction is a copper effect.
• C. This reverses the mechanisms: copper does not reliably inhibit ovulation, and the inflammatory spermicidal effect belongs to copper, not levonorgestrel.
• D. Neither device acts primarily by suppressing GnRH; this is a mechanism more relevant to combined hormonal contraceptives at higher systemic doses.

An adolescent who demonstrates sufficient maturity and understanding to comprehend the nature, risks, and consequences of a medical decision can be considered to have decision-making capacity for that specific intervention, a concept reflected in the evolving capacity principle used in adolescent reproductive health ethics. Confidentiality is a core component of adolescent-friendly health services, as fear of disclosure is a major barrier that, if not addressed, drives adolescents away from safe care toward unsafe alternatives. Breaching confidentiality without the patient's consent, except where there is a safeguarding concern such as abuse or coercion, undermines trust and autonomy.

• A. Requiring parental consent for a minor who has demonstrated capacity to understand the decision is not required and may drive the patient away from safe care.
• C. Informing parents without the patient's consent breaches confidentiality and is not ethically justified in the absence of a safeguarding concern.
• D. Routine ethics committee involvement is unnecessary for a straightforward contraceptive request from a competent adolescent and would cause unjustified delay.